Skip to content
March 28, 2024

Equity.Guru

Investment information for the new generation

Search

MYCO

Mydecine Innovations Group (MYCO.NE) announced they have signed a five-year research agreement with Johns Hopkins University (JHU) School of Medicine. The research will be led by Dr. Matthew Johnson…
Mydecine Innovations (MYCO.NE) announced they are filing a new patent for their MDMA-like compounds. In the press release Mydecine writes that “this expansive patent would allow Mydecine to scale…
Mydecine Innovations Group (MYCO.C) expanded their relationship with Applied Pharmaceutical Innovation (API) to include the University of Alberta in support of multiple drug development and clinical trials, according to…
Mydecine Innovations Group (MYCO.C) announced that they were sponsoring a study called “The neurocognitive effects of low dose psychoactive substances,” at Macquary University in Australia today, according to a…
Mydecine Innovations Group (MYCO.C) launched Mindleap Health, a digital telehealth mobile application today. The intent behind Mindleap is to increase access to mental health services and provide analytics and…
Mydecine Innovations Group’s (MYCO.C) subsidiary Mindleap Health expanded its digital therapeutic services, dealing specifically with addiction, by adding three new programs to its platform. This company is no stranger…
War is a part of human nature. It’s the greatest driver of human innovation, and if we’re inclined to be cynical we could state that it’s the key reason…
Mydecine Innovations Group (MYCO.C) signed a non-binding letter of intent to acquire NeuroPharm, a Canadian-based healthcare company involved in the nascent shroom-space earlier this week. The all-share deal will…